Search Thermo Fisher Scientific
Empowering the People Who Dedicate Their Lives to Microbiology
Thermo Fisher Scientific™ is at the forefront of the global response to coronavirus, working with; governments, agencies, industry partners and researchers globally, to ensure priority access to instruments, consumables, safety supplies and other products to address the outbreak.
Clinical microbiology laboratories have seen an influx of additional tests to identify viral and bacterial infections presenting similar symptoms to coronavirus. Identification of coronavirus as well as similar or related infections is vital to rapidly address the outbreak.
Within Clinical Microbiology we have focused on increasing our manufacturing capacity to deliver viral collection kits and transport media globally. As well as continuing to supply our microbial isolation and identification products and our Antimicrobial Susceptibility Testing (AST) range to maintain antibiotic stewardship even when faced with a pandemic.
Explore the Thermo Scientific™ coronavirus care product mix, from viral and bacterial identification to quality control organisms.
Rule in/out the presence of viral infections which may present similar symptoms to Coronavirus
Product Code | Product name | Usage |
Collection and transport | ||
| R12688 | M4RT (3ml) NPG Swab Kit | Viruses |
| R12596 | M4RT (3ml) w/o Beads Tube | Viruses |
| TV4001V | M4RT (3ml) w/o Beads Tube | Viruses |
| TV4002V | M4RT (3ml) w/o Beads Tube | Viruses |
| R12505 | M4RT (3ml) Tube | Viruses, chlamydiae |
| R12566 | M4RT (3ml) Flock Swab Kit | Viruses, chlamydiae |
Detectand isolate | ||
Xpect™ Flu A & B Test | Influenza A and Influenza B viral antigens | |
Xpect™ RSV Test | Respiratory Syncytial Virus | |
Remel™ Xpect™ Flu A and B Control Swab | Flu A & B Control Swabs | |
Remel™ Xpect™ RSV Control Kit | RSV Control Kit | |
Remel™ PathoDx™ Respiratory Virus Panel | Influenza A; influenza B; .Adenovirus, Parainfluenza 1, 2 and 3, Respiratory Syncytial Virus (RSV) | |
Please contact your Microbiology account manager for product availability
Address an increase in patients with ventilator-associated pneumonia (HAP/VAP), or bacterial respiratory co-infections which can prolong the duration of ventilator use and length of stay.
Every laboratory requires Quality Control (QC) organisms to validate test results against stabilized, viable microorganisms.
Thermo Scientific™ Culti-Loops™ are ready-to-use QC organisms, for use at each stage of the workflow.
Organism | Product code | Collection & transport | Detect & isolate | Identify | Susceptibility test |
Campylobacter jejuni subsp. jejuni ATCC® 33291™ | ✓ | ||||
Candida albicans ATCC® 10231™ | R4601503 |
| ✓ |
| |
Citrobacter freundii ATCC® 8090™ |
| ✓ | |||
Enterococcus faecalis ATCC® 29212™ |
| ✓ | ✓ | ✓ | |
Enterococcus faecalis ATCC® 51299™ |
|
|
| ✓ | |
Escherichia coli ATCC® 25922™ |
| ✓ |
| ✓ | |
Haemophilus influenzae ATCC® 49766™ |
|
|
| ✓ | |
Haemophilus influenzae Type b ATCC® 10211™ | R4603810 | ✓ | ✓ |
| |
Neisseria gonorrhoeae ATCC® 43069™ | ✓ | ||||
Neisseria gonorrhoeae ATCC® 49226™ |
| ✓ | |||
Proteus hauseri ATCC® 13315™ |
| ✓ | |||
Proteus mirabilis ATCC® 12453™ |
| ✓ | |||
Proteus vulgaris ATCC® 8427™ |
| ✓ | |||
Pseudomonas aeruginosa ATCC® 27853™ |
| ✓ |
| ✓ | |
Salmonella enterca subsp. enterca serovar Typhimurium ATCC® 14028™ |
|
| ✓ |
| |
Salmonella enterica subsp. enterica serovarEnteritidis ATCC® 13076™ |
|
| ✓ | ||
Shigella flexneri serovar 2b group B ATCC® 12022™ | ✓ | ||||
Staphylococcus aureus subsp. aureus ATCC® 25923™ |
| ✓ |
| ✓ | |
Staphylococcus aureus subsp. aureus ATCC® 29213™ |
|
|
| ✓ | |
Staphylococcus epidermidis ATCC® 12228™ |
| ✓ | |||
Streptococcus agalactiae group B ATCC® 12386™ |
|
| ✓ | ||
Streptococcus pneumoniae ATCC® 49619™ |
|
|
| ✓ | |
Streptococcus pneumoniae ATCC® 6305™ |
| ✓ | |||
Streptococcus pyogenes ATCC® 19615™ | ✓ | ✓ | ✓ |
| |
Streptococcus sanguinis Type 1 ATCC® 10556™ |
| ✓ |
|
|
Need support identifying your product mix?
Hospital Acquired Pneumonia (HAP) and Ventilator Associated Pneumonia (VAP)
While data is still emerging, reports have suggested that 15% of hospitalized coronavirus patients developed a secondary bacterial infection, the definition of which is: clinical symptoms or signs of pneumonia or bacteraemia with positive culture1.
Among patients who died from coronavirus, 16% of patients had secondary infections2.
Sample collection, transport, identification and accurate treatment is vital to reducing patients' time in hospital and ultimately saving lives.
Be sure of your influenza identification this season
Achieve accurate results within 15 minutes with Thermo Scientific™ Xpect™ Flu A&B Kits.
Stock up now for a reduced workflow back-log with a simple, walk-away procedure.
The ATCC Licensed Derivative Emblem, the ATCC Licensed Derivative word mark and the ATCC catalog marks are trademarks of ATCC. Remel Inc. is licensed to use these trademarks and to sell products derived from ATCC® cultures. The identity, purity, and authenticity of the Licensed Products are exclusively the responsibility of Remel Inc., and not ATCC.
References
1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 11[Online ahead of print].
2. Ruan, Q., Yang, K., Wang, W. et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med (2020). https://doi.org/10.1007/s00134-020-05991-x